Evidence map›Paper›PMID 42062845›Full record

ArticleJournal of nanobiotechnology2026

PDA@MnO

Zinan Zhao, Muladili Mutailipu, Tianxiao Mei, Ran Cui, Yongkun Wang, Fuguo Liu, Chunxiu Dong, Wenwen Jia, Zhongmin Liu, Bo Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zinan ZhaoInstitute for Regenerative Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Muladili MutailipuDepartment of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Tianxiao MeiInstitute for Regenerative Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Ran CuiDepartment of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Yongkun WangDepartment of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Fuguo LiuDepartment of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Chunxiu DongDepartment of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Wenwen JiaShanghai Institute of Stem Cell Research and Clinical Translation, Shanghai, 200120, China.
Zhongmin LiuInstitute for Regenerative Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Bo ChenDepartment of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China. chenbo7349@tongji.edu.cn.
Wenjun LeInstitute for Regenerative Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China. wenjunle@tongji.edu.cn.
Yihui HuInstitute for Regenerative Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China. yihuihu2020@163.com.

Funding

Open Project of Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells 2025SCOF002Shanghai Clinical Research Center for Cell Therapy 23J41900100the National Key Research and Development Program of China 2024YFA1107302the National Natural Science Foundation of China 32371452the National Natural Science Foundation of China 82500605the Natural Science Foundation of Shanghai 23ZR1452100the Research project of Pudong Science and Technology Commission PKJ2020-Y20Young Medical Talents Training Program of Pudong Health Bureau of Shanghai PWRq2022-15
6 · The paper itself

Abstract

Severe acute pancreatitis (SAP) is a life-threatening inflammatory disorder with an approximate mortality rate of 40%. Current therapeutic approaches fail to address its complex pathological microenvironment, necessitating novel synergistic strategies. Although mesenchymal stem cells (MSCs) exhibit therapeutic potential, their efficacy is significantly compromised by SAP-associated oxidative stress, hyperinflammation, and gut dysbiosis. Herein, we engineered MSCs with antioxidant nanozyme PDA@MnO

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationPancreatitisReactive Oxygen SpeciesAnimalsAntioxidantsGastrointestinal MicrobiomeHomeostasisHumansInflammationMaleMiceOxidative StressAntioxidantsReactive Oxygen SpeciesAcute pancreatitisAntioxidant nanozymesEngineered mesenchymal stem cellsGut microbiotaROS-inflammation-microbiota homeostasis

Identifiers

PMID42062845
PMCPMC13285040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.